One of Ethereum's largest holders faces a potential multi-billion dollar liquidation as prices slide, prompting urgent deleveraging moves that could ripple across crypto markets.
Amidst a complex global economic backdrop, Asia's equity markets are hiding gems trading significantly below their estimated intrinsic value. We spotlight three companies—from gaming to aviation and medtech—that our cash flow analysis suggests are deeply discounted, offering potential for investors with an eye on long-term fundamentals.
Iran's Supreme Leader issues his most direct threat yet amid heightened U.S. military presence and stalled diplomacy, while internal crackdown death toll estimates soar.
Following a bold earnings surprise, UPS is betting on a strategic pivot away from low-margin deliveries. While 2026 promises a challenging start, management forecasts a powerful second-half rebound fueled by cost cuts and a focus on healthcare and SMBs.
A federal judge has indicated she is likely to dismiss Elon Musk's xAI lawsuit accusing OpenAI of stealing trade secrets, dealing a significant blow to the tech billionaire's legal offensive against his former AI venture.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
After a punishing year of underperformance and operational setbacks, Baxter International faces a skeptical analyst community. While some see deep value, the consensus remains firmly on hold as the company navigates product challenges and revised guidance.
Meta Platforms announces a 10% workforce reduction in its Reality Labs division, signaling a strategic shift away from its massive metaverse investments toward artificial intelligence and augmented reality, raising questions about the company's future profitability and stock performance.
After two challenging years, Flagstar Bancorp (NYSE: FBC) reported a return to profitability in the fourth quarter of 2025, posting adjusted net income of $30 million. Executives outlined a strategic shift towards commercial lending and a strengthened balance sheet as key drivers for future performance.
Rights groups document a disturbing pattern of Iranian security forces raiding hospitals to arrest injured protesters and the medical personnel treating them, transforming sanctuaries of care into sites of fear and reprisal.
The SAS subsidiary's new enhancement leverages vastly expanded consumer rate shopping data, offering hoteliers granular visibility across room types and distribution channels to refine pricing strategies.
The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.
